Lymphomas are cancers that arise from the cells of the immune system called lymphocytes. There are two main categories, called non-Hodgkin’s lymphoma and Hodgkin’s lymphoma. 90% of all cases are non-Hodgkin’s lymphoma, and Hodgkin’s lymphoma makes about 10%. Twenty years ago, I had a non-Hodgkin’s lymphoma and cured myself. Hodgkin’s lymphoma has a high cure rate of about 75% overall and up to 90% in young patients. The overall average 5-year survival of non-Hodgkin’s lymphoma is 71%. Unfortunately, the incidence of non-Hodgkin’s lymphoma has been increasing in the United States. This increase is probably due to viral infections such as Epstein-Barr virus, hepatitis B and C, and human T-cell lymphoma virus. Lyme infection with borrelia Bergdorf he has been found and mantle cell lymphoma and H. pylori in mucosa-associated lymphoid lymphoma.

There has also been increased exposure to industrial and environmental toxins, including hair dyes, pesticides, and chemical solvents—the most well-established risk factor for the development of non-Hodgkin’s lymphoma is immunosuppression. Autoimmune disease, including lupus, thyroid disease, and rheumatoid arthritis, are also associated with an increased incidence of non-Hodgkin’s lymphoma.

Based on extensive testing, a unique individualized protocol is formulated. Targeted substances to block the cancer pathways along with the alleviation of chemotherapy resistance is of paramount importance. Depletion of myeloid suppressor cells and T regulatory cells will allow the patient’s own immune system to better fight cancer. Low-dose metronomic chemotherapy is utilized to avoid the toxic side effects of traditional high dose maximum tolerated chemotherapy. Low-dose therapy can be used more frequently with minimal side effects without the toxicity seen in conventional chemotherapy doses. Low-dose chemotherapy has been shown to decrease chemotherapy resistance and improve the patient’s underlying immune function. There was also improved adherence by the patient.

Autologous whole cancer vaccines, dendritic cell vaccines are manufactured in the laboratory from the patient’s blood sample containing circulating cancer cells. Supportive oligonucleotide’s (SOT) are also utilized along with targeted chemotherapy, natural substances as well as checkpoint inhibitors.